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This paper examines the effects, causes, symptoms, prevention methods, and
treatments of osteoporosis. Various forms of literature including journal articles and
books were used to research this topic. The information gathered was compacted into a
paper that explained and stated the most relevant and proven facts regarding osteoporosis.
The information was then compacted further when a pamphlet was made consisting of
the most important information. The purpose of the paper was to provide a tool for the
college age population to help prevent a common disease that could affect them later in
life. The pamphlet was assembled to be a quick reference guide of the most important
information and to spread the information more quickly and easily. However, because of
technical dilemmas, the pamphlet was unable to be utilized in the manner that was
planned but could be used in a clinical situation.
Bhavini Patel
Osteoporosis
Osteoporosis is a disease that affects over 28 million people. Half of
the individuals with osteoporosis and its effects are unable to walk
unassisted and 25% are confined to long-term care in a nursing home. 13
Osteoporotic bone loss is responsible for up to 1.5 million fractures a year.
Osteoporosis means "porous bone." Its effects can be potentially
devastating for both the patients and their family. There is a pathological
process that characterizes the disease. Many other diseases increase the
occurrence of the pathological process. In fact, osteoporosis is a secondary
condition to many diseases. It occurs as a result of the effects of other
diseases. Lifestyle related causes also increase the occurrence. There are
also idiopathic causes. Once osteoporosis is suspected, there are many
diagnostic methods to confirm it. Once it has been diagnosed, there are
currently many treatment options available. An overview of osteoporosis
begins with its characterization and prevalence.
The disease is characterized by low bone mass and thinning of bone
tissue. Bone is made up of cortical bone and trabecular bone. Cortical bone
is the dominant type of bone found in the shafts of long bones. Trabecular
bone on the other hand is mostly found in vertebrae, pelvic bone, ends of
bone on the other hand is mostly found in vertebrae, pelvic bone, ends of
long bones, and other t1at bones. Trabecular bone is more metabolically
active than cortical bone. This may be because of its greater surface area.
Trabecular bone is therefore more responsive and affected by changes in
minerals.
As a person develops, their bone develops to a level called the peak
bone mass, it is the maximum mass of bone that the body is going to reach.
After this stage is reached, the slow phase of bone loss begins. It begins
around age 40 for cortical bone and 5-10 years earlier for trabecular bone.
In women a "transient accelerated postmenopausal" phase of bone loss also
occurs. This process occurs due to estrogen deficiency that accompanies
menopause. It results in a disproportionate loss of trabecular bone as
compared to cortical bone. On average, 25% is lost in both the trabecular
and cortical compartment for both men and women. However, post-
menopausal women loose an additional 10% from the cortical compartment
and an additional 25% from the trabecular compartment around the age of
40. This additional loss increases as women get older. Therefore, overall,
women loose 35% from cortical bone and 50% from trabecular bone. Evista,
Fasomax, and hormone replacement therapy are some of the recent more
common drugs that are used to decrease bone loss in women that occur as a
result of estrogen deficiency. 13
Bone remodeling is also affected by age. Bone formation and
resorption occurs in bone remodeling units. In the remodeling cycle, the
first thing that occurs is that the flattened lining cells are activated. They
retract and expose the underlying bone and recruitment of the osteoclast
precursor cells occurs. The osteoclasts (bone destroying cells) then migrate
toward the expose area of the bone. During the following 1-3 weeks, the
cells form a tunnel in the cortical bone or a lacuna on the surface of
trabecular bone. The osteoclasts then disappear and are replaced by
osteoblasts (bone forming cells). The osteoblasts fill in the "holes" during a
period of 3-4 months. These changes occur all throughout life.
Osteoporosis occurs as a result of an imbalance at each bone-remodeling
unit. Imbalance starts to occur around the age of 40, same as when the slow
phase of bone loss begins. An increase in the number of bone remodeling
units leads to an increase of bone loss. Bone turnover time (the time it takes
for bone to break down and rebuild itself) is slowed down.I" In the slow
phase of bone loss, the osteoblasts fail to completely fill in the "holes"
formed by the osteoclasts. This leads to thinning of trabecular bone,
however, their connectivity is still present. In the accelerated
postmenopausal phase of bone loss, there is trabecular perforation and loss
of the connectivity. 13 Bone density tests can be done to determine how
much perforation there is. They will be discussed in detail later.
If the bone density is extremely low, bone starts to resemble thin lace
(the spaces within bone become enlarged), it becomes fragile and is easily
fractured. This process can continue unnoticed until a fracture occurs. In
fact, fractures do not occur until bone density has fallen below values found
in young adults. Normal bone density is 1.0 gm per sq em for vertebrae and
the proximal femur and 0.4 gm per sq em for the ultra distal radius. The
lower the level of bone density, the higher the risk of fracture. 13
There are many things that increase chances of getting osteoporosis:
-bone mass is affected by genetic and lifestyle factors
-unbalanced diets and disordered eating
-low calorie intake and excessive exercise'<
-women who are thin tend to have lower bone density and are at
more risk for fractures.V
-calcium and vitamin D deficiency'<
d fici J?-estrogen e lClency -
-women who enter menopause at an early age are more
likely to loose more bone and women who enter menopause
with lower bone mass are at a higher risk for developing
. 12osteoporosis,
S id j)- teroi use-
-Too much or too little thyroid medication"
-women with type I diabetes are thought of to be at higher risk
f . 12or osteoporosis
-Smoking interferes with the body's ability to absorb calcium I 2
-Increased alcohol intake may increase the risk for
.j)osteoporosis -
In fact, smoking and alcohol intake doubles the risk of
developing osteoporosis. 13 The risk is significantly greater among
people who drink than those who do not. 15 Young people who drink
alcohol have been shown to have thinner bones than other young
people of the same age who do not drink alcohol. 13 The risk is
increased by a factor of 1.007 for each ounce year (1 ounce per day
for a year) of cumulative exposure. The risk is also significantly
greater among people who smoke than those who do not. The risk is
increased by a factor of 1.009 for each pack year (1 pack per day for a
) f ISyear 0 exposure.
Obesity on the other hand, is not a factor that increases the risk for
osteoporosis. In fact, it helps decrease it. The risk among obese men was
less than a third of that among non-obese men. There may be two possible
mechanisms for this. Obese men have increased serum estrogen levels due
to enhanced conversion in peripheral fat of testosterone to estradiol and
androstenedione to estrone. This may protect against bone loss. IS Also,
excess body weight increases the loading stress to the spine, which
stimulates bone formation. In postmenopausal obese women, there is
increased conversion of adrenal androgens to estrogens in fat tissue and this
leads to decreased bone loss. 13
Another factor that increases the risk for osteoporosis is the presence
of many other diseases. There are many connective tissue diseases related to
osteoporosis. Osteogenesis imperfacta is an inherited disease associated
with blue sclera, deafness, thin skin, and impaired formation of type I
collagen. The onset is during childhood. The disease results in premature
spinal osteoporosis. Other common connective tissue diseases also include
homocystinuria and autosomal recessive disorder. These diseases result in
an increase in homocysteine and other metabolites that interfere with cross
linkage of collagen. This interference with collagen may lead to
. h 13osteoporotic c anges.
There are also many types of endocrine diseases that are associated
with osteoporosis. Endogenous or exogenous hyperadrenocorticism
decreases bone formation and increases bone resorption. Hyperthyroidism
increases bone turnover, however, this is also accompanied with an increase
in bone formation.
Gastrointestinal diseases may lead to osteoporosis because of the
effects of the impairment in the absorption of calcium and vitamin D. Bone
marrow disorders also produce effects of osteoporosis in 10% of patients.
There is an increase in local production of lymphotoxin, interleukin-l, and
other cytokines by bone marrow cells. Osteoporosis may also occur when
there is cancer related to bone marrow because of the above mentioned
increases in local production.
There are many types of osteoporosis. Idiopathic Juvenile
osteoporosis occurs in boys and girls during the ages of 8-14. There is
usually an acute and active phase. The acute phase usually runs 2-4 years,
then remits. In the active phase, there is growth arrest and multiple
fractures. The etiology of this disease is unknown, but some do believe that
hormones may be a factor although there are cases of the disease that
occurred in children before puberty (when hormones are most active). 13
Achondroplasia (dwarfism) is a different disease characterized by a defect in
bone and cartilage and is not related to Idiopathic Juvenile osteoporosis.
Idiopathic osteoporosis in young adults occurs in both sexes equally.
The cause of this disease is unknown. It has the etiology of several distinct
disorders. There are usually multiple vertebral fractures over 5-10 years
along with a loss of height of up to 6 inches. The serum values for calcium,
phosphorus, and alkaline phosphatase are all found to be normal.
Also, there are both low and high bone turnover rates. The disease
characteristics are broad and varied. 13
There are two types of involutional osteoporosis. Involutional
osteoporosis occurs as a result of the aging process. It is characterized by a
progressive decline of normal physiological functioning. Type I is
postmenopausal and occurs in women 15-20 years after menopause. The
rate of trabecular bone loss in these women is 2-4 times greater than that of
other postmenopausal women of the same age without fractures. However,
the rate of cortical bone loss is only slightly greater. The following occurs:
accelerated bone loss, decreased secretion of parathyroid hormone, and
increased secretion of calcitonin. This leads to decreased calcium
absorption. There are many new drugs that address these occurrences, they
will be discussed later.
Type II osteoporosis occur in both men and women age 70 and over.
Women get it two times as much as men. It results from slow bone loss over
the course of several decades. The bone density values in parts of the
appendicular skeleton fall below normal. This may suggest an even loss in
cortical and trabecular bone. Age related factors play an important role in
this type of osteoporosis. There is decreased osteoblast function and
decreased calcium absorption. The vertebral fractures that occur are the
wedge type. These fractures lead to dorsal kyphosis. Trabecular bone
thinning is responsible for the painless vertebral deformation. 13
Bone loss occurs without symptoms, therefore, osteoporosis is not
usually discovered until a patient has a fracture. 10 Therefore, the following
are common symptoms of the disease: back pain caused by vertebral
compression, height loss, spinal deformity(kyphosis with a loss of 4-8 inches
in height), fractures of vertebrae(about one per year in the beginning of the
disease), hips, wrists, and other bones. 13
After osteoporosis is suspected, typically bone mineral density tests
are done for the following reasons: to confirm the diagnosis, estimate the
severity of bone loss, and determine the effectiveness of treatment.
Single energy quantitative computed tomagraphy (QCT) measures
bone density by using CT scanners and a calibration phantom. Accuracy is
poor and reproducibility is satisfactory. There is also a high level of
radiation exposure. Radiation exposure for a single-energy CT measurement
is 100-300 mrem but may go as high as 500-1000 mrem'
A dual-energy QCT is more accurate, however the reproducibility is
poorer and there is a higher level of radiation exposure. The radiation
exposure is between 5-10 mrem. This is about 1110 of a standard chest x-
ray, so the measure can be taken fairly often without excessive radiation
exposure. It has the ability to measure exclusively the metabolically active
trabecular bone in the center of the vertebral body."
Transmission scanning, dual-photon absorptiometry, allows bone
density to be measured independently of soft tissue thickness and measures
the entire vertebrae. It emits two photoelectric peaks that allow bone density
to be measured independently of soft tissue thickness and composition."
The most recent technique used to measure bone density is the dual-
energy x-ray absorbtiometry. It has better reproducibility, shorter scan time,
and is capable of measuring the density of the entire skeleton. 13 It uses two
x-ray beams with different levels of energy. After eliminating soft tissue
absorption, the absorption of each beam by bone is used to calculate the
bone mineral density. It is a portable device that is easy to use and
. 4convenient.
Bone turnover rates can be measured by assessing the levels of
biochemical markers associated with bone resorption and formation that are
released into blood or urine. These tests are inexpensive and non-invasive.
Some newly recognized markers for bone resorption measured in urine
include: pyridinium cross links of collagen, deoxypyridinoune, and
pyridinoline. They are highly sensitive and specific for the degradation of
bone collagen. Serum markers include bone specific alkaline phosphatase
and osteocalcin. They are also sensitive and bone formation specific.
Together these tests provide an index of bone turnover rate.:'
After the disease has been confirmed, the following are the treatment
options that are currently available. Many of these treatment options can
also be applied to help prevent the disease from occurring in the first place.
One of the most common is exercise that keeps muscles strong and toned.
The best type of exercise to help keep and maintain healthy, strong bones is
weight-bearing activities. They help maintain existing bone by stimulating
bone formation. It is also encouraged to incorporate flexibility and balance
training in exercise programs. It helps maintain bone mass and reduces the
risk of falling by 25%3
One study assessed the effect of back extensor strengthening on
osteoporosis. Thirty-six women over the age of 40 were studied. They all
had radiological evidence of either osteopenia (precursor to osteoporosis) or
osteoporosis. The study found that those with higher levels of activity (such
as back extensor strengthening) had greater bone mineral density than those
who had low activity levels (no back extensor strengthening). Therefore
physical activity promotes or maintains bone mineral density'
Another study was done to determine whether standing posture
exercises could improve thoracic kyphosis and balance in women with
osteoporosis. Forty-eight postmenopausal women 59-89 years of age were
studied. All of the women were diagnosed with osteoporosis. Control
subjects continued their normal activities. Exercise subjects performed five
standing posture exercises daily. The study suggests that standing posture
exercises may be effective in improving one measure of balance in women
diagnosed with osteoporosis. Further studies would be required to establish
a long-term effect. 14 Therefore doing standing posture exercises after being
diagnosed with osteoporosis could improve a women's thoracic kyphosis
and balance.
Another type of exercise treatment is the use of orthotics. A
randomized controlled study was done to determine the effect of two
different types of back orthoses on back strength in patients with
osteoporosis. The study included 45 women between the ages of 43 and 87.
They were randomly assigned to one of three groups. Each group was in the
program for a total of 16 weeks. The first group utilized a conventional
thoracolumbar support, with the back orthotic used continuously whenever
patients were out of bed. The second group was called the Posture Training
Group, they wore a weighted kypho-orthosis for four hours twice a day. The
third group used no orthotic. All three groups went through body mechanic
training, deep breathing training, and seated back extension instruction.
Back extensor strength and grip strength were measured before, during, and
after training. Patients in the Posture Training Support group showed
significant improvement in back extensor strength. The study concluded
that the posture training support device increases back extensor strength.
This may help prevent compression fractures by providing the weight
bearing forces needed to prevent fractures. 7 Therefore, a posture training
support device might be a good option for those who have weak back
extensors as a result of osteoporosis.
Eating a nutritionally balanced diet while young prevents the onset of
adult chronic diseases such as heart-related diseases. Meals should be rich in
calcium and vitamin D. This prevention method is also used to treat cases of
osteoporosis. A study done on medical nutrition therapy used people with
osteoporosis. Medical nutritional therapy included an evaluation of the
patient's health history, social status, and nutrient intake. Based on the
assessment, a nutrition care plan was developed and implemented.
Nutritional intervention in hip fracture patients showed a significant
decrease in mortality and hospital stay time. II
Another one of the most common methods of treating osteoporosis is
the use of medications. These include Evista, Fosamax, and hormone
replacement therapy. However, administration of estrogen is the most
common treatment of osteoporosis. Estrogen helps prevent bone loss by
acting directly on bone cells to reduce bone resorption. A dose of
0.3mg/day, with calcium supplements has been proven to be as effective as
higher doses of estrogen. However, there are some side effects of hormone
replacement therapy. Some of these side effects include breast tenderness,
mood disturbances, vaginal bleeding, and migraine headaches.
Postmenopausal administration of estrogen decreases the occurrence of
vertebral and hip fractures by 50%.13 The exact mechanism of how estrogen
prevents bone loss is not known, but there have been some theories: it
promotes calcitonin synthesis, it increases vitamin D availability, it inhibits
the release of resorptive agents, and it inteferes with bone resorption through
bone cell receptors."
Raloxifene has been proven to reduce the risk of vertebral fractures in
women with osteoporosis. Raloxifene hydrochloride is a nonsteroidal
benzothiophene that binds to estrogen receptors and inhibits bone resorption
without stimulating the uterine endometrium in postmenopausal women. In
fact, 60mg/day of the drug decreased the risk of a vertebral fracture by 30-
50%.8 7,705 women between the ages of 31 and 80 participated in this
study. All of the women had been post-menopausal for at least two years
and had osteoporosis."
Daily oral treatment with 10mg of biophosphonate alendronate
sodium (Fasamax) progressively increases the bone mass of the spine, hip
and total body in postmenopausal women with osteoporosis according to
randomized double blind, placebo-controlled multi-center study.
Bisphosphonates are non-hormonal bone specific agents that bind to bone
surfaces and inhibit bone resorption. They are the best bone protection
agent. They also work regardless of the patient's age or bone mineral
d . 13ensity.
Alendronate prevents vertebral fractures, progression of vertebral
deformities and loss of height. The study included 994 post-menopausal
women with osteoporosis, each partcipant took 5 or 10 mg/day for 3 years or
20 mg for 2 years followed by 5mg for the third year. All the women also
took 500mg/day of calcium. Findings from the study included the following:
Bone mineral density increased in the lumbar spine, femoral neck,
trochanter, and total body in all the alendronate groups and decreased in the
placebo group, the difference in bone mineral density in the spine was 8.8%,
7.8% in the trochanter, and 2.5% in the whole body, and alendronate also cut
the incidence of new vertebral fractures in half (3.2% in the alendronate
group, and 6.2% in the control group)."
There was a study done to review the use of alendronate in the
postmenopausal women with osteoporosis. The review came to the
conclusion that alendronate (along with calcium) is associated with
improvement in bone density in hip sites. It is in the hip because this is
where there is a greater degree of cortical bone present. Alendronate is
beneficial to those who do not respond well to other treatments such as the
use of calcium and vitamin D or estrogen."
Fluoride is another drug used for osteoporosis. It stimulates
osteoblastic proliferation and formation of new bone. However, excessive
exposure to fluoride may cause abnormal bone formation, micro fractures,
and gastric bleeding. "Cyclical, intermittent use of a lower dose of less
bioavailable, slow-release sodium fluoride has been shown to maintain
serum fluoride at appropriate levels and to stimulate normal bone
formation." This study was a randomized, placebo-controlled study of a
slow-release form of sodium fluoride to assess its effect on spinal fracture.
Women who had radiological evidence of osteopenia and osteoporosis were
randomly selected to receive either fluoride and calcium or a placebo. The
treatment group received two cycles of slow-release sodium fluoride, 25 mg
twice daily (12 months on therapy, 2 months off) and calcium citrate, 400
mg calcium twice daily. Concurrent treatment with estrogen was similar in
both groups (13 of 48 patients in the treatment group and 16 of 51 in the
placebo group). In the fluoride group, the L2-L4 bone mineral contented
increased substantially by 4-6% per year in all four years of the study. The
L2-L4 bone mineral content in the placebo group did not change
substantially in any year. Body height decreased significantly more in the
placebo group. No significant difference was apparent in minor
gastrointestinal and musculoskeletal side effects. The conclusion was that
the delayed release of fluoride along with intermittent withdrawal of fluoride
and the provision of calcium citrate is a safe treatment and has a positive
response on bone formation. The short-term withdrawal of fluoride has been
shown to overcome the attenuated osteoblastic activity that occurs with
continuous fluoride therapy.' Therefore, fluoride used intermittently along
with calcium citrate may be used to treat osteoporosis.
In conclusion, osteoporosis is a complex pathological process that
occurs in bone. There are many diseases that increase the likelihood of
getting osteoporosis. There are also many lifestyle factors that increase the
likelihood. Diagnosis of the disease can be done using different methods,
CT scans being one of the most common. After diagnosis has been
confirmed, there are many treatment options available including hormone
replacement therapy. Overall, osteoporosis can be a devastating disease, but
there are many ways that its effects can be diminished, the most important
being the individual.
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